Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses

Abstract

Dendritic cell-based cancer vaccines (DC vaccines) have been proved efficient and safe in immunotherapy of various cancers, including melanoma, ovarian and prostate cancer. However, the clinical responses were not always satisfied. Here we proposed a novel strategy to prepare DC vaccines. In the present study, a fusion protein SNU containing a secretin-penetratin (SecPen) peptide, NY-ESO-1 and ubiquitin was designed and expressed. To establish the DC vaccine (DC-SNU), the mouse bone marrow-derived DCs (BMDCs) were isolated, pulsed with SNU and maturated with cytokine cocktail. Then peripheral blood mononuclear cells (PBMCs) from C57BL/6 mice inoculated intraperitoneally with DC-SNU were separated and cocultured with MC38/MC38 NY-ESO-1 tumor cells or DC vaccines. The results show that SNU was successfully expressed. This strategy made NY-ESO-1 entering cytoplasm of BMDCs more efficiently and degraded mainly by proteasome. As we expected, mature BMDCs expressed higher CD40, CD80 and CD86 than immature BMDCs. Thus, the PBMCs released more IFN- γ and TNF- α when stimulated with DC-SNU in vitro again. What's more, the PBMCs induced stronger and specific cytotoxicity towards MC38 NY-ESO-1 tumor cells. Given the above, it demonstrated that DC-SNU loaded with SecPen and ubiquitin-fused NY-ESO-1 could elicit stronger and specific T cell immune responses. This strategy can be used as a platform for DC vaccine preparation and applied to various cancers treatment.

The safety and anti-tumor effect of multiple peptides-pulsed dendritic cells combined with induced specific cytotoxic T lymphocytes for patients with solid tumors

“…CTLs can directly kill tumor cells quickly, efficiently and specifically through the cytokine secretion ( 33 , 34 ). As reported, the secretion of IFN-γ was associated with the response of tumor-specific T cells, and exerts anti-tumor effects by inhibiting tumor-cell proliferation and promoting tumor cell apoptosis ( 35 – 38 ). As a consequence, the production of IFN-γ exhibits an intensely synergistic boost to antigen-specific immune responses during immunotherapy ( 39 ).…”

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

“…DCs are critical APCs that initiate naïve T cells, which play a crucial role in bridging innate and adaptive immunity 21 . DCs are divided into several important subgroups: conventional DCs mainly serve to prime naïve T cells; plasmacytoid DCs (pDCs) can produce large amounts of type I interferon (IFN) to participate in antiviral immunity; monocyte-derived dendritic cells (moDCs) can present antigens to effector T cells and secrete cytokines; Langerhans cells (LCs) are epidermal DCs that can present antigens to induce T cell immunity 22 .…”

Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy

“…They have additional advantages in establishing immune memory and preventing tumor recurrence ( 99 ). At present, cancer vaccines, represented by DC vaccines, have achieved successful clinical results in the immunotherapy of various malignancies, including OC, melanoma, and prostatic cancer ( 100 ). DC vaccines that target MUC1 and NY-ESO-1 have been used to treat patients with OC.…”